Trial Profile
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Avapritinib (Primary) ; Regorafenib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms VOYAGER
- Sponsors Blueprint Medicines
- 25 Apr 2023 Results published in the Annals of Oncology
- 07 Jun 2022 Results assessing circulating tumor DNA (ctDNA) analyses, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 08 Oct 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record. (2021-09-15)